Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14675504 | 0.80 | KMT2A (0.52) | KMT2ALMNATSHRALDH1A1HPGD | |
| SCHEMBL8704293 | 0.79 | KMT2A (0.50) | KMT2ATSHRALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL15514630 | 0.79 | KMT2A (0.50) | KMT2ALMNATSHRALDH1A1MEN1 | |
| SCHEMBL6254665 | 0.77 | LMNA (0.53) | KMT2ALMNATSHRALDH1A1MAPK1 | |
| SCHEMBL8358267 | 0.77 | HPGDS (0.49) | KMT2AHTTLMNATSHRRIPK1 | |
| SCHEMBL8698619 | 0.76 | LMNA (0.53) | LMNATSHRALDH1A1HPGDMAPT | |
| SCHEMBL11405723 | 0.75 | KMT2A (0.46) | KMT2ATSHRALDH1A1MEN1HPGD | |
| SCHEMBL8540917 | 0.73 | LMNA (0.49) | KMT2AHTTLMNARIPK1ALDH1A1 | |
| SCHEMBL29222241 | 0.73 | TSHR (0.49) | KMT2ALMNATSHRALDH1A1MEN1 | |
| SCHEMBL8540915 | 0.73 | LMNA (0.49) | KMT2AHTTLMNARIPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3426256-A1 | METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR EVENTS AND RELATED DISEASES USING SGLT-2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2019-01-16 | — | — | EP | disclosed |
| EP-3217987-A1 | SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS WITH RENAL IMPAIRMENT OR CHRONIC KIDNEY DISEASE | Merck Sharp & Dohme Corp. (US) | 2017-09-20 | — | — | EP | disclosed |
| WO-2017155841-A1 | METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR EVENTS AND RELATED DISEASES USING SGLT-2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-09-14 | — | — | WO | disclosed |
| WO-2016077126-A1 | SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS WITH RENAL IMPAIRMENT OR CHRONIC KIDNEY DISEASE | MERCK SHARP & DOHME CORP. (US) | 2016-05-19 | — | — | WO | disclosed |
| US-8324406-B2 | Antitumoral dihydropyran-2-one compounds | PHARMA MAR, S.A. (ES) | 2012-12-04 | — | — | US | disclosed |
| EP-2496583-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | Pfizer Inc. (US) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011051864-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER INC. (US) | 2011-05-05 | — | — | WO | disclosed |
| US-20100048690-A2 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR, S.A. (ES) | 2010-02-25 | — | — | US | disclosed |
| US-20090186938-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR, S.A. (ES) | 2009-07-23 | — | — | US | disclosed |
| EP-2032551-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR, S.A. (ES) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007144423-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR, S.A. (ES) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048690-A2 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | RPLP1, PKD1, KRAS | KMT2A 4182/4885HTT 432/4885LMNA 1728/4885 |
| US-20090186938-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | RPLP1, PKD1, KRAS | KMT2A 4182/4885HTT 432/4885LMNA 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.